Results 121 to 130 of about 1,930,055 (355)

Interplay of integrins and selectins in metastasis

open access: yesMolecular Oncology, EarlyView.
Here we review the role of integrins and their interplay with selectins in metastasis. The efficacy of integrin‐targeted therapies may be reduced in tumors where metastasis relies heavily on selectins. In certain tumors, integrins and selectins exhibit a synergistic interaction during intraperitoneal dissemination.
Diana Maltseva   +2 more
wiley   +1 more source

Minimum Bias and Early QCD at ATLAS [PDF]

open access: yesarXiv, 2010
The early minimum bias and the QCD results from the ATLAS experiment in the LHC are presented.
arxiv  

Evaluation of atlas-based segmentation of hippocampi in healthy humans [PDF]

open access: yes, 2009
Introduction and aim: Region of interest (ROI)-based functional magnetic resonance imaging (fMRI) data analysis relies on extracting signals from a specific area which is presumed to be involved in the brain activity being studied.
Chupin, M.   +5 more
core   +3 more sources

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

open access: yesMolecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen   +12 more
wiley   +1 more source

Higgs boson search at ATLAS [PDF]

open access: yesarXiv, 2012
The status of the ATLAS Higgs boson search using about 5 fb^-1 of data recorded in 2011 is summarized. Proceedings from Physics at the LHC 2012 (Vancouver).
arxiv  

Expected Tracking Performance of the ATLAS Inner Tracker at the High-Luminosity LHC [PDF]

open access: yesJINST 20 (2025) P02018
The high-luminosity phase of LHC operations (HL-LHC), will feature a large increase in simultaneous proton-proton interactions per bunch crossing up to 200, compared with a typical leveling target of 64 in Run 3. Such an increase will create a very challenging environment in which to perform charged particle trajectory reconstruction, a task crucial ...
arxiv   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

open access: yesMolecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu   +12 more
wiley   +1 more source

An Atlas of subgroup lattices of finite almost simple groups [PDF]

open access: yesarXiv, 2013
We announce an atlas of subgroup lattices of almost simple groups and present two algorithms that were used to produce the atlas.
arxiv  

Beyond digital twins: the role of foundation models in enhancing the interpretability of multiomics modalities in precision medicine

open access: yesFEBS Open Bio, EarlyView.
This review highlights how foundation models enhance predictive healthcare by integrating advanced digital twin modeling with multiomics and biomedical data. This approach supports disease management, risk assessment, and personalized medicine, with the goal of optimizing health outcomes through adaptive, interpretable digital simulations, accessible ...
Sakhaa Alsaedi   +2 more
wiley   +1 more source

Could the systemic immune-inflammation index be a new biomarker of inflammation in children with asthma?

open access: yesMedicine Science
Asthma is a disease with a complex etiology that is caused by genetic and environmental factors. More recently, the importance of changes related to the systemic immune-inflammation (SII) index has been recognized.
Omer Okuyan   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy